RIVER EDGE, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), is pleased to announce that it has received the prestigious 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award, for its rapid growth, progressive technology, and strategic product development.
Nephros was recognized for its ability to develop products that meet market demands. Nephros's breakthrough hemodiafiltration technology has resulted in rapid revenue growth as well as a new therapy for end-stage renal disease (ESRD). Its OLpur(TM) H2H(TM) Module and MD 220 filter received approval under an investigational device exemption (IDE) from the FDA in January 2007. By October, clinical trials were initiated at the Columbia University Dialysis Center in New York. In June 2008, Nephros completed a pivotal trial for its hemodiafiltration products and submitted a 510(k) application in November.
Full article >> http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/01-14-2009/0004954634&EDATE=
Thursday, January 15, 2009
Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment